Inventiva Pharma

company

About

Inventiva is a biopharmaceutical company with several drug candidates at clinical and preclinical stage.

  • 101 - 250

Details

Last Funding Type
Post-IPO Debt
Last Funding Money Raised
€50M
Industries
Biopharma,Biotechnology,Clinical Trials,Medical,Medical Device
Founded date
Jan 1, 2011
Number Of Employee
101 - 250
Operating Status
Active

Inventiva Pharma is a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with significant unmet medical needs in the areas of fibrosis, lysosomal storage disorders and oncology.

They have built a pipeline backed by a discovery engine with an extensive library of proprietary molecules, a wholly-owned research and development facility and a team with significant expertise and deep experience in the development of compounds that target nuclear receptors, transcription factors and epigenetic modulation. Leveraging these assets and expertise, they are advancing two clinical candidates in three indications, as well as a deep pipeline of earlier stage programs.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
€52.30M
Inventiva Pharma has raised a total of €52.30M in funding over 2 rounds. Their latest funding was raised on May 16, 2022 from a Post-IPO Debt round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
May 16, 2022 Post-IPO Debt €50M 1 European Investment Bank Detail
Sep 19, 2016 Grant €2.30M 1 Detail

Investors

Number of Lead Investors
Number of Investors
1
2
Inventiva Pharma is funded by 2 investors. European Investment Bank and Agence National de la Recherche are the most recent investors.
Investor Name Lead Investor Funding Round
European Investment Bank Yes Post-IPO Debt
Agence National de la Recherche Grant